Elkhorn Partners Limited Partnership Makes New $125,000 Investment in Biohaven Ltd. (NYSE:BHVN)

Elkhorn Partners Limited Partnership purchased a new position in shares of Biohaven Ltd. (NYSE:BHVN) during the 2nd quarter, HoldingsChannel reports. The firm purchased 3,600 shares of the company’s stock, valued at approximately $125,000. Biohaven accounts for 0.1% of Elkhorn Partners Limited Partnership’s portfolio, making the stock its 26th largest holding.

Other large investors also recently bought and sold shares of the company. Perceptive Advisors LLC increased its holdings in Biohaven by 129.4% during the 4th quarter. Perceptive Advisors LLC now owns 1,725,047 shares of the company’s stock worth $73,832,000 after purchasing an additional 973,227 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Biohaven by 20.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 518,904 shares of the company’s stock worth $22,209,000 after purchasing an additional 86,890 shares during the period. Vanguard Group Inc. increased its holdings in Biohaven by 280.5% during the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock worth $345,031,000 after purchasing an additional 4,650,702 shares during the period. CWM LLC increased its holdings in Biohaven by 1,893.4% during the 2nd quarter. CWM LLC now owns 14,552 shares of the company’s stock worth $505,000 after purchasing an additional 13,822 shares during the period. Finally, Oak Ridge Investments LLC increased its holdings in Biohaven by 197.6% during the 2nd quarter. Oak Ridge Investments LLC now owns 22,000 shares of the company’s stock worth $764,000 after purchasing an additional 14,607 shares during the period. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

BHVN has been the topic of several recent research reports. Sanford C. Bernstein started coverage on Biohaven in a report on Wednesday, September 4th. They set an “outperform” rating and a $55.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a research report on Monday, August 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $59.00 price objective on shares of Biohaven in a research report on Wednesday, September 4th. UBS Group lowered their price objective on Biohaven from $55.00 to $54.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Finally, Morgan Stanley started coverage on Biohaven in a research report on Wednesday, July 24th. They set an “overweight” rating and a $58.00 price objective for the company. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Biohaven currently has a consensus rating of “Buy” and an average target price of $54.70.

Insider Transactions at Biohaven

In other Biohaven news, Director John W. Childs bought 28,400 shares of the business’s stock in a transaction dated Thursday, July 18th. The stock was acquired at an average cost of $35.67 per share, with a total value of $1,013,028.00. Following the purchase, the director now owns 2,339,741 shares in the company, valued at approximately $83,458,561.47. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 16.00% of the company’s stock.

Biohaven Stock Down 0.0 %

Shares of NYSE BHVN opened at $39.01 on Wednesday. Biohaven Ltd. has a 52-week low of $16.45 and a 52-week high of $62.21. The business has a 50-day moving average price of $38.12 and a 200 day moving average price of $41.27. The stock has a market cap of $3.44 billion, a PE ratio of -5.71 and a beta of 1.30.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($3.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92). Sell-side analysts anticipate that Biohaven Ltd. will post -8.92 earnings per share for the current year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.